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Abstract β-arrestins	 are	 so-called	 hub	 proteins:	 they	 make	 complexes	 with	 many	 different	partners,	 assembling	 functional	 complexes,	 and	 thereby	 fulfilling	 their	 biological	function.	The	importance	of	this	process	in	G	protein-coupled	receptor	(GPCR)	signalling	has	 been	 fully	 demonstrated	 for	 many	 different	 receptors.	 For	 direct	 interactions,	determining	 the	 interface	 regions,	 on	 β-arrestins	 and	 on	 the	 partners,	 is	 crucial	 for	understanding	 the	 function	 of	 the	 complex.	 Indeed,	 this	 brings	 information	 on	which	proteins	 can	 interact	 simultaneously	 with	 β-arrestins,	 or	 on	 the	 contrary,	 which	partners	are	exclusive.	We	present	here	a	method	in	two	steps:	protein-protein	docking	allows	finding	a	limited	number	of	peptides	predicted	to	be	involved	in	the	interaction;	and	then	experimental	that	might	be	used	for	validating	the	prediction.		
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1. Introduction β-arrestins	play	key	roles	in	G	protein-coupled	receptor	(GPCR)	signalling	through	their	interactions	 with	 hundreds	 of	 proteins	 (1).	 Characterizing	 the	 interaction	 regions	between	β-arrestins	and	their	partners	is	an	important	step	in	the	understanding	of	the	functional	 roles	of	 these	 interactions.	 In	particular,	 it	 allows	determining	 the	partners	that	 are	 in	 competition	 with	 each	 other	 (XOR),	 and	 those	 whose	 interactions	 are	compatible	(AND),	and	can	thus	bind	simultaneously	on	a	single	β-arrestin	molecule	(2).	This	knowledge	can	lead	to	the	understanding	of	how	different	signalling	pathways	can	be	 triggered	 simultaneously,	 or	 on	 the	 contrary	 compete	 each	 other	 (3,	 4),	 or	 how	mutations	in	one	partner	can	affect	to	various	extents	its	different	partners	(5,	6).	The	 gold	 standard	 in	 interface	 determination	 is	 the	 determination	 of	 complex	 3D	structures,	 either	 by	 crystallography,	 or	 using	NMR.	However,	 this	 represents	 a	 lot	 of	work	and	requires	the	production	of	both	proteins	at	high	yield.	Moreover,	in	the	case	of	signalling	 proteins,	 such	 as	 β-arrestins	 and	 their	 partners,	 the	 affinities	 are	 generally	low,	 and	 stabilizing	 the	 complex	 can	 be	 tricky.	 Aside	 from	 the	 3D	 structure,	 a	widely	used	experimental	method	is	to	evaluate	the	binding	between	one	partner	and	mutants	of	the	other	one,	either	in	terms	of	affinity,	or	in	terms	or	relative	binding	as	compared	to	 the	wild	 type.	However,	 single	mutations,	 especially	 alanine	mutations,	 can	 lead	 to	undetectable	modulation	of	the	affinity,	although	they	affect	amino	acids	involved	in	the	interaction.	Moreover,	the	throughput	of	such	a	method	is	very	low.	A	higher	throughput	can	 be	 achieved	 using	 peptide-array	 based	 methods	 (7–9),	 in	 which	 overlapping	peptides	of	one	partner	are	arrayed	on	solid	support	and	exposed	to	the	second	partner.	This	 can	be	 followed	by	alanine-scanning	of	positive	peptides	 to	refine	 the	 interaction	map.	Recently,	mass	spectrometry-based	approaches	have	been	developed	(10,	11).	The	principle	 is	 to	 submit	 the	 complex	 either	 to	 hydrogen/deuterium	 exchange,	 or	 to	enzymatic	 digestion,	 and	 to	 identify	 through	 mass	 spectrometry	 peptides	 that	 are	protected	by	the	interaction.	However,	these	methods	are	time-consuming	and	require	specialized	equipment	and	skills.	We	have	recently	developed	a	method	for	determining	the	interaction	regions	in	protein	complexes,	which	allows	us	to	predict	and	validate	the	geometry	of	 the	assembly	of	β-arrestin	with	the	receptor,	c-Src	and	the	ERK	signalling	module	(Raf,	MEK	and	ERK)(12).	In	 addition,	 results	 obtained	 from	 such	 an	 approach	 allows	 us	 to	 make	 hypotheses,	which	 can	 be	 experimentally	 validated,	 for	 instance	 on	 the	 mechanism	 of	
phosphorylation	of	residue	T383	in	β-arrestin	upon	activation	of	the	receptor(13).	This	method	consists	of	two	main	steps.	First,	a	computational	method,	based	on	an	in-house	protein-protein	 docking	 algorithm	 (14–16),	 allows	 determining	 four	 regions	 of	 the	sequences	of	each	partner	possibly	involved	in	the	interaction.	Second,	these	regions	are	used	to	design	peptides	that	are	used	for	refinement	and	experimental	validation	of	the	prediction.	 	This	 experimental	 validation	 can	 be	 conducted	 using	 various	 protocols.	 Although	positive	 results	 using	 only	 one	 method	 are	 enough	 for	 the	 validation,	 interactions	between	 a	protein	and	a	peptide	 are	not	easily	detected.	We	give	here	 three	different	possible	validation	methods,	ranked	in	order	of	difficulty,	but	also	of	sensitivity.	The	first	method	 we	 describe	 here	 is	 GST-pulldown	 approach,	 which	 is	 used	 to	 visualize	competition	between	the	partner	and	a	peptide,	for	binding	to	β-arrestin	(figure	1A).	If	positive,	the	results	of	GST-pulldown	validate	the	prediction	of	the	interface.	 	However,	GST-pulldown	is	not	a	very	quantitative	method	and	requires	large	quantities	of	 both	 purified	 proteins.	 As	 an	 alternative,	 we	 suggest	 using	 Homogenous	 Time	Resolved	 Fluorescence	 (HTRF)	 to	 assess	 the	 competition	 (figure	 2A).	 HTRF	 combines	fluorescence	 resonance	 energy	 transfer	 technology	 (FRET)	 with	 time-resolved	measurement	 (TR).	 In	TR-FRET	assays,	 a	signal	 is	 generated	 through	FRET	between	a	donor	 (long-lived	 fluorescence)	 and	 an	 acceptor	 (short-lived	 fluorescence)	 molecule	when	in	close	proximity	to	each	other	(i.e.	the	distance	between	the	two	fluorophores	is	less	 than	 1.8	 x	 the	 radius	 of	 Förster,	 i.e.	 <10Å	 or	 1nm).	 Time	 delay	 (50-150	microseconds)	 between	 the	 initial	 light	 excitation	 and	 fluorescence	 measurement	minimizes	the	contribution	of	all	non-specific	short-lived	fluorescence	emissions.	Buffer	and	media	 interference	 is	dramatically	reduced	by	dual-wavelength	detection,	 and	 the	final	signal	is	proportional	to	the	extent	of	product	formation.	Specific	fluorophores	are	used	in	HTRF	forming	different	TR-FRET	systems	like	Europium	cryptate	donor	(Eu3+)	or	Terbium	donor	(Tb2+).	These	ions	are	not	fluorescent	on	their	own,	since	they	need	a	light-collection	 device	 to	 be	 excited.	 HTRF	 technology	 has	 been	 applied	 to	 many	antibody-based	assays	including	GPCR	signaling	(cAMP	and	IP1),	kinases,	cytokines	and	biomarkers,	bioprocess	(antibody	and	protein	production),	as	well	as	assays	for	protein-protein,	protein-peptide,	and	protein-DNA/RNA	interactions.	Here,	we	describe	how	to	measure	 FRET	 differences	 between	 two	 purified	 tagged-proteins	 in	 the	 presence	 of	competing	peptides	designed	to	interact	with	either	β-arrestin	or	its	protein	partner.	
If	the	affinity	between	β-arrestin	and	its	partner	is	high,	the	affinity	of	the	peptide	might	not	 be	 sufficient	 for	 competition.	 In	 that	 case,	 we	 have	 shown	 that	 biolayer	interferometry	can	be	used	to	evaluate	the	specificity	of	the	peptide	(figure	3A).	Biolayer	interferometry	is	very	similar	in	its	principles	to	surface	plasmon	resonance	(SPR),	but	has	 the	 great	 advantage	 of	 being	 a	 non-fluidic	 system,	which	 is	 easier	 to	 handle	 and	maintain.	It	relies	on	the	detection	of	the	association	of	molecules	on	a	surface	at	the	tip	of	a	biosensor,	constituted	mainly	of	an	optic	fiber	(1).	This	biosensor	is	first	dipped	in	a	well	containing	the	first	partner,	which	associates	to	the	surface,	and	this	association	can	be	observed	 through	 the	analysis	of	 light	 reflected	at	 the	 tip	of	 the	biosensor	 (2).	The	biosensor	 can	 then	be	dipped	 in	a	 second	well	 containing	 the	 second	partner,	 and	 the	association	with	the	first	partner	can	be	measured	using	the	same	principle	(3).	Finally,	the	biosensor	can	be	dipped	 in	a	well	containing	only	buffer,	which	allows	monitoring	the	dissociation	of	the	two	partners.	In	our	case,	the	first	partner	is	the	peptide	designed	to	 interfere	 with	 the	 association	 of	 β-arrestin	 with	 its	 partner,	 and	 biolayer	interferometry	is	used	to	measure	the	association	of	β-arrestin	with	this	peptide.	We	use	biotinylated	peptides,	which	can	be	loaded	on	streptavidin	biosensors.	The	advantage	is	that	 the	 interaction	affinity	between	biotin	and	streptavidin	 is	very	high,	guaranteeing	that	 the	dissociation	observed	at	step	3	 is	 that	of	 the	two	 loaded	components,	and	not	the	dissociation	of	the	first	component	from	the	biosensor.	 		  
2. Materials Unless	otherwise	mentioned,	all	chemicals	are	from	Sigma	Aldrich.	 	
2.1 GST glutathione S-transferase (GST)-pulldown 1. Plasmids	and	bacteria:	GST-Raf1-RBD	expressed	 from	pGEX-2T	was	generously	provided	by	Dr.	Véronique	Fafeur	 (Pasteur	 Institute,	Lille).	The	Raf1-RBD	 (Ras-binding	 Domain)	 corresponds	 to	 amino	 acids	 51	 to	 131	 of	 Raf1	 and	 is	 the	minimum	 domain	 required	 for	 binding	 to	 Ras-GTP.	 The	 pGEX-2T	 plasmid	 (GE	Healthcare,	Buckinghamshire,	UK)	was	used	as	a	negative	control.	C(6His)-tagged	human	 β-arrestin	 1	 was	 from	 Gentaur	 (San	 Jose,	 CA,	 USA).	 Chemo-competent	NEB-5α	bacteria	were	 from	New	England	Biolabs,	 Ipswish,	MA,	USA).	Agar	(LB-Agar	Lennox)	plates	and	L-broth	(LB-medium	Lennox	powder),	both	purchased	at	 MP	 Biomedicals,	 Illkirch,	 France,	 contained	 100	 μl/ml	 ampicillin	 (stock-solution	100	mg/	ml).	 	2. Lysis	buffer	used	for	protein	production	in	E.	coli:	250	mM	NaCl,	10	mM	MgCl2,	10	mM	 EDTA,	 1	%	 Triton,	 250	 μg/ml	 lysozyme,	 10	 mM	 DTT,	 1	 mM	 PMSF,	 3.4	 U	DNAse	 I,	 1	 X	 protease	 and	 phosphatase	 inhibitor	 cocktail	 II	 (Thermo Fisher 
Scientific Inc. Waltham, MA, USA),	 in	 phosphate-buffered	 saline	 (PBS).	 This	buffer	has	to	be	prepared	extemporaneously	and	kept	on	ice	until	use.	3. Buffers	 used	 for	 GST	 (glutathione	S-transferase)	 pull-down.	 a)	 fusion	 protein	binding	buffer:	10	mM	Tris-HCl	pH	8.0,	100	mM	NaCl,	0.5	%	NP40,	20	mM	EDTA,	1	 mM	 PMSF	 or	 1	 X	 protease	 and	 phosphatase	 inhibitor	 cocktail	 II.	 b)	 HNTG	protein-protein	 interaction	 buffer:	 20	 mM	 Hepes,	 pH	 7.9,	 50	 mM	KCl,	 2.5	 mM	MgCl2,	1	mM	DTT,	10	%	glycerol,	1	X	protease	and	phosphatase	inhibitor	cocktail	II.	If	prepared	in	advance,	omit	the	protease/	phosphatase	inhibitors	in	the	stock	solutions.	4. Laëmmli	buffer	2X	was	prepared	with	8	%	SDS,	5	%	β-mercapto-ethanol,	10	%	glycerol	(w/v),	32	mM	Tris-HCl	pH	6.8,	0.01	%	bromophenol	blue,	and	stored	at	room	 temperature.	 Western	 blot	 blocking	 solution	 was	 made	 with	 PBS/0.1	Tween	20	with	5%	bovine	serum	albumin.	 	5. Polyclonal	 anti-β-arrestin	primary	 antibody,	 diluted	 1:	2,000,	was	 from	Abcam,	Cambridge,	England.	IRDye	Alexa	fluor	680-labelled	secondary	antibody,	diluted	
1:	 15,000,	was	 from	Licor,	 Lincoln,	NE,	USA.	 Anti-GST	 antibody,	 diluted	1:	 500,	was	from	Life	technologies,	Carlsbad,	CA,	USA.	 	6. Competing	 peptides,	 synthesized	 by	 Genecust	 Laboratories	 (Dudelange,	Luxembourg),	 were	 designed	 following	 prediction	 of	 the	 docking	 interface,	 as	described	above	in	section	3.1.	
2.2 Homogeneous Time Resolved Fluorescence (HTRF) Prepare	all	solutions	(purified	myc-β-arrestin1	(0.180	µg/µl,	Origene	#TP321737)	and	ERK	 peptides	 (100	 µg/µl))	 in	 PBS	 (1X)-Tween	 20	 0.1	 %	 at	 4°C	 and	 store	 purified	proteins	at	-80°C,	acceptor-	and	donor-fused	antibodies	and	peptides	at	-20°C.	Prepare	all	 reagents	 in	 384-well	 plate	 for	 a	 final	 volume	 of	 20	 µl	 which	 contains	 10	 µl	 of	 2X	purified	 protein	 ([myc-β-arrestin1]initial	 =	 0.4ng/µl),	 5	 µl	 of	 4X	 peptide	 ([ERK	peptide]initial	 =	 50mM)	 and	 5	 µl	 of	 4X	 HTRF	 donor-coupled	 antibody	 ([α-c-myc	 Tb	cryptate]initial	=	30ng/µl,	Cisbio))	and	acceptor-coupled	antibody	([streptadivin-D2]initial	=	1000ng/µl],	Cisbio).	1. Prepare	10	ml	of	PBS	(1X)-Tween	20	0.1	%:	add	1	ml	of	PBS	10X	to	8.9	ml	of	water,	then	add	100	µl	of	Tween	20.	Mix	gently	to	homogenate	solution	and	store	at	4°C;	2. Gently	thaw	purified	proteins	on	ice;	3. Dilute	lyophilized	peptide	in	DMSO,	work	on	ice	and	store	at	-20°C;	 	4. Use	white	flat	low	volume	384-well	plate	to	work	with	20	µl	final	volume.	5. Settings	measurements	 are	 defined	 by	 using	Mikrowin	 2010	software	 and	 relative	energy	transfer	rate	of	each	condition	is	measured	on	microplate	reader	MITHRAS²	LB	943	(Berthold	technologies	GmbH	and	Co.Kg,	Germany).	
2.3 Interferometry 1. 96-well	 black	 plates,	 without	 lid	 (ref	#	 1608130,	 Greiner	 Bio-One,	 Kremsmünster,	Austria)	2. Kinetic	Buffer	10X	(ref	#18-1092,	50	ml,	Pall	forte	Bio,	Fremont,	CA,	USA)	3. SA	(streptavidin)	biosensors	(Pall	forte	Bio,	Fremont,	CA,	USA)	4. Octet	RED96	System	(Pall	forte	Bio,	Fremont,	CA,	USA)	5. Octet	Software	9.0	version	(Pall	forte	Bio,	Fremont,	CA,	USA)	6. Biotinylated	 peptide	 α	 (=ligand,	 relevant	 peptide),	 stock	 suspension	 at	 50	 mM	 in	dimethylsulfoxide	(DMSO)	7. Protein	β	(=	analyte,	β-arrestin	in	our	example),	stock	suspension	at	1	µg/µl	 	
8. Biotinylated	peptide	γ	(non-relevant	ligand),	stock	suspension	at	50	mM	in	DMSO		  
3. Methods 
3.1 Predicting the possible interaction regions and designing validation peptides 1. Get	the	structure	files	corresponding	to	the	two	interacting	partners,	for	example	from	RCSB	(http://www.rcsb.org)	(see	Notes	1	and	2).	2. If	 the	 files	 contain	more	 than	 one	 chain,	 for	 example	 if	 the	 atomic	 coordinates	correspond	 to	 a	 homo-multimer,	 or	 if	 the	 structures	 have	 been	 determined	 in	complex	with	another	partner,	 remove	 irrelevant	 chains	 from	 file.	Heteroatoms	should	also	be	removed.	If	the	partner	is	constituted	of	more	than	one	chain	(for	example	 an	 antibody,	 comprising	 heavy	 and	 light	 chains),	 it	 should	 be	renumbered	as	a	single	chain	(see	Note	3).	3. Choose	the	partner	that	will	not	move	(usually	designated	as	the	“receptor”)	and	the	 partner	 that	 will	 move	 around	 the	 receptor	 partner	 (designated	 as	 the	“ligand”).	This	choice	does	not	change	the	prediction.	However,	all	the	proposed	docking	poses	will	be	superimposed	on	the	receptor	partner.	Consequently,	if	you	are	more	interested	on	the	interface	on	one	of	the	partners,	choose	it	as	receptor.	If	you	are	interested	in	both	interfaces,	choose	the	smallest	partner	as	ligand,	the	computations	will	be	a	bit	faster.	 	4. Run	PRIOR	(see	Note	4).	 	5. PRIOR	outputs	a	 file	named	 “peptides.txt”,	which	 is	 a	 list	of	peptides.	From	our	benchmarks,	one	of	 the	 first	 four	peptides	does	belong	to	the	 interface,	and	the	three	 others	 are	 often	 part	 of	 the	 interface	 also.	 Thus,	 it	 is	 recommended	 to	consider	using	the	four	top-ranked	peptides.	 	6. Each	 peptide	 computed	 by	 PRIOR	 is	 15	 residues	 long.	 Each	 peptide	 should	 be	used	 for	 validation,	 but	 also	 a	 peptide	 starting	 and	 ending	 three	 residues	upstream	and	a	peptide	starting	and	ending	three	residues	downstream.	Indeed,	we	have	often	observed	that	the	computed	peptide	might	not	be	soluble,	but	the	upstream	 and/or	 downstream	peptides	 are.	 Thus,	 designing	 three	 peptides	 for	each	predicted	interacting	residues	stretch	increases	the	chance	to	have	at	least	one	peptide	suitable	for	experimental	validation	(see	Note	5).	
3.2 GST-pulldown  1. Producing	GST-Raf1-RBD	fusion	protein	in	E.	coli.	 	
a. On	 day	 1,	 transform	 competent	 NEB-5α	 bacteria	with	 either	 a	 pGEX-2T	plasmid	encoding	GST-	Raf1-RBD	or	an	empty	plasmid	encoding	GST	alone,	which	is	used	as	a	control.	Spread	bacteria	on	agar	plates	containing	100	μg/ml	ampicillin	and	incubate	overnight	(ON)	at	37°C.	b. On	 day	 2,	 amplify	 bacteria	 by	 picking	 one	 colony	 into	 25	 ml	 L-broth	containing	 100	 μg/ml	 Ampicillin.	 Incubate	 ON	 at	 37°C	 in	 a	 shaking	incubator	at	200	rpm.	c. On	day	3,	dilute	the	25	ml	of	culture	into	225	ml	LB/Amp,	and	grow	3	h	at	37	°C	at	200	rpm.	Ten	(10)	ml	of	the	250	ml	culture	are	stored	at	4°C	until	step	1.d	as	a	control	of	the	non-induced	condition.	In	the	remaining	240	ml,	induce	 protein	 expression	 by	 adding	 2.4	 ml	 EtOH	 (1	 %	 final	concentration)	 +	 600	 µl	 IPTG	 (250	 µM	 final	 concentration)	 and	 grow	bacteria	for	3	h	at	37°C	in	a	shaking	incubator	at	200	rpm.	d. Proceed	 with	 induced	 and	 non-induced	 bacteria	 lysis	 on	 ice.	 Centrifuge	bacteria	culture	at	2,500	g	 for	30	min	at	4°C,	in	Nalgene	bottles.	Recover	the	 pellet	 and	 centrifuge	 the	 supernatant	 again	 for	 20	min.	 Both	 pellets	should	 be	 recovered	 and	 pooled	 in	 lysis	 buffer	 (500	 µl	 for	 10	 ml	 of	culture),	 in	a	15-ml	Falcon	tube.	 Incubate	ON	at	4°C	on	a	rotating	wheel.	The	 next	 day,	 the	 lysates	 are	 sonicated	 three	 times	 for	 30	 sec	 on	 ice,	centrifuged	 for	 one	 hour	 at	 12,000	 g	 and	 filtered	 on	 0.22	 µm	 filters.	Aliquots	of	non-purified	GST-fusion	protein	controls	(60	µl	for	the	induced	condition	and	12.5	µl	for	the	non-induced	condition)	are	diluted	in	equal	volumes	 of	 2X	 Laëmmli	 buffer	 (v/v)	 and	 stored	 at	 -20°C	 until	 use	 (see	
Note	6).		 2. In	vitro	protein-protein	interaction.	 	a. Preparation	of	Glutathione-Sepharose	4B	beads.	Pipette	20	µl	of	slurry	beads	(50%	in	EtOH)	per	ml	of	 initial	bacteria	culture.	Centrifuge	the	beads	at	500	g	for	5	min,	resuspend	them	in	10	ml	PBS,	and	incubate	at	4°C	on	a	rotating	wheel	for	1.5	hour.	Centrifuge	the	beads	again	at	500	
g	for	5	min	and	re-suspend	in	an	equal	volume	of	PBS.	 	b. Purification	 of	 the	 fusion	 protein.	 Incubate	 the	whole	 bacteria	 lysate	with	4.8	ml	of	slurry	beads	prepared	in	3.2.2.a,	and	with	200	µl	for	the	
non-induced	 condition	 at	 4°C	 on	 a	 rotating	 wheel	 for	 30	 min.	Centrifuge	 at	 500	g	 for	 5	min,	 then	wash	 the	beads	 twice	with	 PILB.	Beads	are	next	saturated	with	5	ml	of	10	%	BSA	under	rotation	at	4°C	for	10	min,	washed	once	 in	1	ml	PILB,	and	centrifuged	at	500	g	 for	5	min	before	removing	the	supernatant.	Beads	can	be	used	immediately,	once	 extensively	 dried	 for	30	min	 at	 37°C.	 Alternatively,	 they	 can	 be	stored	 as	 50	 µl	 dried	 aliquots	 at	 -20°C	 for	 future	 use,	 after	 first	 re-suspending	 them	 in	PILB	and	centrifuging	 them	again	at	500	g	 for	5	min.	 	c. The	reaction	mix	comprises	25	ng	of	recombinant	human	His-tagged	β-arrestin	 1,	 50	 µl	 of	 dried	 beads	 coated	with	 either	GST-Raf1-RBD	or	GST,	 and	 0.5	 mM	 (see	Note	 7)	 of	 one	 of	 the	 competing	 peptides	 or	control	 peptide	 (Figure	 1A).	 These	 quantities	 correspond	 to	 a	 β-arrestin/	peptide	molar	ratio	of	10	to	1.	The	volume	is	completed	to	1	ml	 with	 HNTG	 buffer,	 and	 the	 reaction	 mix	 is	 placed	 at	 4°C	 on	 a	rotating	wheel	 for	1	hour	(see	Note	8).	The	beads	are	then	washed	6	times	with	1	ml	HNTG	(each	time,	centrifuge	at	500	g	for	5	min).	 	d. Competing	 peptides	 cover	 amino	 acids	 30-38	 of	 human	 β-arrestin	 1	(HIDLVEPVD)	 or	 aminoacids	 65-74	 (KQRTVVNVRN)	 on	 Raf1.	 The	control	peptide	corresponds	to	amino	acids	69-77	(DVLGLSFRK)	of	β-arrestin	1,	 a	region	 that	 is	outside	of	 the	predicted	Raf1/β-arrestin	1	interface.	 		 3. After	 the	 last	 centrifugation,	 dried	 beads	 are	 re-suspended	 in	 2X	 Laëmmli	buffer	(v/v),	boiled	at	100°C	for	30	min,	and	centrifuged	for	10	min	at	12,000	
g.	Recover	the	supernatants	(avoid	pipetting	beads)	and	load	them	onto	10	%	SDS-PAGE	gels.	After	the	transfer	of	the	resolved	proteins	onto	nitrocellulose	membrane,	 dip	 the	 latter	 in	 10	ml	 of	 blocking	 solution	 for	 one	 hour	 at	 RT,	then	 incubate	 the	 membrane	 ON	 with	 a	 polyclonal	 anti-β-arrestin	 primary	antibody	 and	 then	with	 IRDye	Alexa	 fluor	 680-labelled	 secondary	 antibody,	all	 diluted	 in	 blocking	 buffer.	 Protein	 loading	 homogeneity	 is	monitored	 by	stripping,	 washing	 and	 reprobing	 membranes	 with	 a	 polyclonal	 anti-GST	antibody	against	GST-raf1-RBD.	 	
3.3 HTRF Carry	out	all	procedures	on	ice	to	preserve	protein	and	peptide	stability.		 1. Peptide-based	 validation	 of	 the	 protein	 partner	 interaction	 area.	 Several	peptides	 are	 designed	 at	 the	 interface	 region	 of	 each	 partner.	 The	 protocol	given	here	allows	testing	the	specific	interaction	of	the	peptides	belonging	to	the	 interface	region	of	one	partner	with	the	second	partner.	This	protocol	 is	illustrated	here	for	the	interaction	of	ERK	peptides	with	β-arrestin	1	(Figures	2A-C).	e. Dilute	β-arrestin	1	to	2	ng/µl	in	PBS(1X)-0.1%	tween	20	and	dispense	5	µl	per	well	in	a	low	bottom	384	well	plate.	 	f. Dilute	the	ERK	peptides	to	2	mM	in	PBS(1X)-0.1%	Tween	20	and	dispense	10	µl	per	well.	g. Cover	the	plate	with	adhesive	and	aluminum	foils	and	incubate	overnight	at	4°C	under	smooth	agitation.	h. Mix	 3	 ng	 of	 the	 donor-coupled	 antibody	 (or	 protein)	 and	 50	 ng	 of	 the	acceptor-coupled	antibody	(or	protein)	in	5	µl	and	dispense	in	the	well.	 	i. Incubate	1h	at	room	temperature	and	keep	the	plate	several	days	at	4°C	(see	Notes	10-13).	 	2. Open	microplate	reader	MITHRAS²	LB	943	(Berthold	technologies	GmbH	and	Co.Kg,	Germany)	and	Mikrowin	2010	software.	3. The	reader	performs	two	sequential	readings	at	620	nm	(donor)	and	665	nm	(acceptor)	 emission	 wavelengths.	 In	 mean	 windows	 of	 Mikrowin	 2010	software,	 click	 on	 “Instrument”	 in	menubar,	 then	 in	 “Excitation	 filter	 slide”,	introduce	bar	with	excitation	filter	620nm.	Then	click	in	“Emission	filter	slide”	and	introduce	bar	with	emission	filter	665nm.	4. Load	a	predefined	protocol	HTRF	by	clicking	on	“Open	Template”	tab	in	mean	window.	Select	TR-fluorescence,	then	HTRF	Tb_red_348.par	file.	5. Define	measurements	sequence	parameters	in	“Option”	tab.	 	6. A	dialog	box	opens	with	two	tabs	:	Samples	and	Measurement,	 	First	click	on	“Samples”,	enter	parameters	of	plate	format:	 	- in	plate	type	:	Berthold	384-No33505,	- in	plate	mode	:	Measurement	 	
- in	Measure	order	:	By	Rows	and	click	on	Meander.	 	Then	select	wells	for	measurements	Second	 to	 features	 of	 the	measurement	 operation,	 click	 on	 “Measurement”.	Three	 columns	 appear.	 Left	 column	 describe	 the	 settings	 of	 the	 chosen	operation.	Check	that	pre-select	steps	of	measurement	are	selected	:	“Delay”,	“Skake”,	“Lumi.Label”,	“Lumi.kinetic”,	“Fluor.kinetic”	and	“Fluor.kinetic”.	In	middle	column,	double	click	in	“HTRF-Tb-red”	to	verify	parameters:	- Counter	time	:	1.00sec	- Counter	:	photon	- Use	:	filter	- Reading	position	:	top	- Aperture	TRF	filter	:	384	- Excitation	filter	:	340x26	HTRF	Tb	cryptate	- Excitation	optic	:	default	- Emission	filter	:	620xm10	Eu	cryptate	- Cycle	Time	:	2000µs	- Delay	Time	:	50µs	- Reading	Time	:	400µs	- Click	second	measurements	- Excitation	filter	:	340x26	HTRF	Tb	cryptate	- Emission	filter	:	665xm7uv	XL665,	APC	- Operation	mode	:	By	plate	7. Before	 to	 start	 reading,	 give	 name	 of	 your	 experiment	 in	 “Plate	 ID”	 in	 the	toolbar	8. Click	“START”,	introduce	your	place	in	the	reader.	9. The	live	data	measurement	can	be	displayed	by	clicking	on	“measurement”	10. Calculate	energy	transfer	rate	(see	Note	13)	
3.4 Interferometry 1. Dilute	the	biotinylated	peptides	α	and	γ	(called	“ligands”),	in	1X	kinetic	buffer	to	the	determined	concentrations	(see	Notes	14	and	15).	200	µl	per	well	are	needed.	 		
2. Dilute	the	protein	β	(called	“analyte”)	in	kinetic	buffer.	Five	association	curves	(i.e.	5	concentrations	of	 the	analyte)	are	necessary	to	measure	a	reliable	Kd	(see	Note	16).	One	well	must	be	 left	empty,	 i.e.	with	no	analyte,	only	kinetic	buffer.		3. Load	 the	 200	 µl	 of	 protein	 solutions	 or	 kinetic	 buffer	 in	 a	 black	 plate	according	to	Figure	3B		4. Soak	 2	 columns	 of	 biosensors	 in	 200	 µl	 of	 kinetic	 buffer	 in	 a	 black	 plate	positioned	under	the	sensor	tray.		5. Open	the	Octet	Data	Acquisition	9.0	software,	open	a	new	experiment	wizard	and	enter	your	plate	scheme	in	“plate	definition”.		6. In	“assay	definition”,	set	the	experiment	up	as	follows	(Figure	3B):	j. set	a	60	sec	baseline	in	column	1	k. set	a	600	sec	loading	step	in	column	2	l. set	a	60	sec	baseline	in	column	1	m. set	a	60	sec	baseline	in	column	3	n. set	a	600	sec	association	in	column	4	o. set	a	600	sec	dissociation	in	column	3	p. click	on	“new	assay”.	The	following	steps	will	appear	in	a	different	color	q. set	a	60	sec	baseline	in	column	5	r. set	a	600	sec	loading	step	in	column	6	s. set	a	60	sec	baseline	in	column	5	t. set	a	60	sec	baseline	in	column	7	u. set	a	600	sec	association	in	column	4	v. set	a	600	sec	dissociation	in	column	7	All	the	steps	are	performed	at	30°C	and	under	1000	rpm	shaking.		7. In	“sensor	assignment”,	locate	the	2	biosensors	columns,	containing	peptides	α	and	γ,	as	they	appear	in	the	sensor	tray.	The	2	columns	should	appear	in	2	different	colors,	 the	same	colors	as	 the	steps	before.	By	right-clicking	on	the	
second	 biosensor	 column	 (the	 one	 loaded	 in	 the	 non-relevant	 peptide	 γ),	select	“reference”.		 8. Start	reading.	 		9. Open	 the	 Data	 Analysis	 9.0	 software	 and	 load	 your	 experiment	 in	 “data	selection”.		10. Each	curve	must	be	 corrected	 twice:	 first	by	 subtracting	 the	 curve	obtained	from	the	wells	without	protein	β	(line	A	according	to	figure	3B),	and	second	by	 subtracting	 for	 each	 curve	 obtained	 on	 the	 relevant	 peptide	 (α)	 its	counterpart	on	the	non-relevant	peptide	(γ).	To	do	so,	 in	“processing”,	go	to	the	 step	 1	 part	 and	 click	 on	 “sensor	 selection”.	 In	 the	 “sensor	 tray”,	 the	biosensors	 should	 appear	 as	 sample	 sensors	 in	 the	 column	1	 and	 reference	sensors	in	column	2.	If	not,	change	their	settings	by	right	clicking	on	them.	In	the	 “sample	 plate	map”,	 right-click	 on	 the	 “no	 analyte”	well	 and	 set	 it	 as	 a	reference	sensor	as	well.	Be	sure	that	the	selection	boxes	next	to	the	reference	sensor	column	and	the	non-analyte	well,	are	selected.	 		11. In	“processing”,	go	to	step	2.	Select	“subtraction”	and	“double	reference”.	The	subtraction	calculation	formula	should	appear	in	the	box.		12. In	“processing”,	go	to	step	3.	Select	“Align	Y	axis”	on	“association”.		13. Click	on	“Process	data”.		14. In	 “processed	 data”,	 select	 the	 fitting	model	 corresponding	 to	 your	 protein	sample	(typically	the	1:1	model).	The	analysis	must	be	performed	for	all	the	curves	at	once.	To	do	so,	select	“global	analysis”	and	“by	color”	(it	implies	that	all	the	curves	should	appear	in	the	same	color;	to	do	so,	select	them	all,	right-click	and	select	a	random	color).	The	Kd	and	other	parameters	are	shown	in	the	table	(see	Notes	17-19,	figure	3C).	 		
	  
4. Notes 1. The	 list	 of	 PDB	 files	 corresponding	 to	 a	 given	 protein	 appears	 on	 the	 Uniprot	page	of	 the	protein,	 in	 the	“Structure	section”.	 If	 there	 is	more	than	one	choice,	the	structure	corresponding	to	the	largest	region	should	be	chosen.	In	case	there	are	 multiple	 files	 corresponding	 to	 this	 criterion,	 the	 one	 with	 the	 lowest	resolution	should	be	preferred.	Finally,	read	carefully	the	corresponding	Protein	Data	 Bank	 (http://www.rcsb.org	 (17))	 page,	 in	 order	 to	 see	 if	 the	 structure	contains	ligands,	inhibitors,	glycosylations,	etc.		2. If	the	3D	structure	of	one	of	the	partners	has	not	been	determined,	it	is	possible	to	use	the	structure	of	a	very	close	homologue.	This	is	the	case	for	β-arrestins	1	and	2:	the	3D	structure	of	the	human	proteins	has	not	been	determined,	but	only	those	 of	 the	 bovine	 homologues.	 However,	 the	 only	 sequence	 differences	between	 human	 and	 bovine	 proteins	 lie	 in	 the	 C-terminal	 tails,	 which	 are	 not	present	in	the	3D	structures.	Consequently,	the	bovine	structures	can	be	used.		3. To	remove	chains	and	hetero-atoms,	PyMol	software	(https://www.pymol.org/)	can	be	used.		 4. At	this	step,	PRIOR	can	be	replaced	by	another	protein-protein	docking	method,	but	 there	 will	 be	 no	 automated	 peptide	 design.	 In	 that	 case	 this	 can	 be	 done	manually:	from	the	predicted	complex	3D	structure,	list	the	amino	acids	in	each	partner	 that	 are	 involved	 in	 the	 interaction.	 For	 each	 stretch	 of	 residues	predicted	 to	 be	 at	 the	 interface,	 design	 a	 15-aa	 long	 peptide	 by	 extending	 this	stretch	in	both	directions	(towards	the	N-	and	C-term).	This	procedure	can	also	be	applied	for	an	“educated-guess”	of	the	interface	regions.		 5. Regarding	the	design	of	peptides,	the	rules	given	in	“Methods”	should	be	applied	with	discernment,	and	some	exceptions	should	be	raised	(Figure	4):	a. If	the	computed	peptide	starts	at	position	1	of	the	sequence,	no	upstream	peptide	 should	be	used.	Conversely,	 if	 the	 computed	peptide	ends	at	 the	last	residue	of	the	partner,	no	downstream	peptide	should	be	used.	
b. It	sometimes	happens	that	 the	computed	peptide	corresponds,	 in	 the	3D	structure,	to	a	sequence	stretch	whose	central	part	is	buried,	which	means	that	the	two	extremities	are	predicted	to	belong	to	the	interface	region.	In	that	case,	either	the	peptide	should	be	ignored,	or	two	different	peptides	should	be	generated	by	extending	upstream	and	downstream,	in	order	to	define	 15	 residue-long	 peptides	whose	 central	 regions	 are	 exposed	 and	correspond	to	the	extremities	of	the	original	peptide.	c. If	 the	 peptide	 corresponds	 to	 a	 helical	 region,	 it	 should	 be	 ignored.	 The	reason	 is	 that	 a	15	residue-long	peptide	will	only	exceptionally	 fold	as	a	helix.	 	d. Although	 there	 is	 no	 absolute	 rule	 to	 predict	 the	 solubility	 of	 a	 peptide,	you	 should	 avoid	 sequences	 starting	or	 ending	with	hydrophobic	 amino	acids.	 If	 the	 computed	 peptide,	 or	 the	 upstream/downstream	 peptide,	start	 or	 end	 with	 hydrophobic	 amino	 acids,	 try	 shifting	 upstream	 or	downstream.	 Alternatively,	 the	 peptides	 can	 be	 shortened.	 The	 affinity	having	 a	 tendency	 to	 decrease	with	 the	 length	 of	 the	 peptide,	 the	 short	peptides	tend	to	be	less	favourable	than	longer	ones.	However,	here	also	there	 is	 no	 prediction	 rule,	 and	 sometimes	 very	 nice	 results	 can	 be	obtained	with	8	residue-long	peptides.		6. Each	step	of	the	fusion	protein	production	and	binding	to	the	Glutathione	beads	can	be	monitored	by	SDS	PAGE	10	%	and	Coomassie	blue	staining,	by	comparing	induced	 and	 non-induced	 conditions,	 as	 well	 as	 purified	 and	 non-purified	conditions.	 Serial	 dilutions	 of	 BSA	 can	 be	 used	 as	 a	 standard	 to	 estimate	 the	amount	of	purified	GST-	Raf1-RBD.		 7. We	assayed	several	concentrations	of	competing	peptide,	and	an	inhibitory	effect	was	 visible	 from	 0.5	 mM.	 At	 the	 same	 concentration,	 no	 effect	 of	 the	 control	peptide	is	observed.		 8. β-arrestins	are	"sticky"	proteins.	Hence,	when	investigating	β-arrestin	interaction	partners	in	cell	lysates,	only	a	5	min	interaction	time	is	enough,	in	order	to	avoid	
non-specific	binding.	However,	with	recombinant	purified	protein,	this	time	had	to	be	extended	to	one	hour.		 9. ERK	peptides	sequences	:	erk-antibarr-0	 ISPFEHQTY	erk-antibarr-1.1	 RVAIKKISPFEHQTY	erk-antibarr-1.2	 IKKISPFEHQTYCQR	erk-antibarr-1.3	 ISPFEHQTYCQRTLR	erk-antibarr-2.1	 IRDILRASTLEAMRD	erk-antibarr-2.2	 ILRASTLEAMRDVYI	erk-antibarr-2.3	 ASTLEAMRDVYIVQD		 10. As	initial	concentrations	of	purified	protein	are	often	lower,	calculate	how	much	ng	of	protein	you	need	for	a	triplicate.	Then,	prepare	an	intermediate	solution	at	1:10	with	PBS(1X)-Tween	0.1	%,	for	each	protein	in	a	final	volume	of	50	µl	or	20	µl.	From	1:10	solutions,	prepare	mix	of	both	proteins	and	adjust	the	final	volume	with	PBS(1X)-Tween	0.1%	to	deposit	20	µl	or	10	µl	in	one	well	of	a	96-well	plate	or	a	384-well	plate,	respectively.	 		11. To	 verify	 that	 HTRF-coupled	 antibodies	 recognize	 specifically	 tagged-proteins,	prepare	conditions	with	an	 irrelevant	antibody.	Also,	 to	make	sure	that	 there	 is	no	 cross-talk	 between	 secondary	 antibodies,	 prepare	 triplicate	wells	with	 only	antibodies.	 Finally,	 to	 subtract	 medium	 background,	 prepare	 triplicate	 of	PBS(1X)-Tween	20	only.		12. Preincubation	allows	the	peptides	to	associate	with	the	proteins.	This	association	might	be	perturbed	by	the	antibodies	used	for	detection	since	the	affinities	of	the	peptides	for	the	proteins	are	low	(usually	in	the	high	micromolar	range),	whereas	the	affinities	of	antibodies	binding	to	their	targets	are	very	high.	Do	not	forget	to	prepare	 each	 condition	with	 and	without	 peptides.	 Since	 some	 complexes	may	gain	in	stability	over	time,	it	is	recommended	to	keep	the	plate	at	4°C	and	make	repeated	measures	along	3-4	days	(Figure	2C).	 		
13. After	 plate	 reading,	 results	 are	 present	 in	 an	 Excel	 table	 were	 two	 sequential	readings	at	620nm	and	665nm	emission	wavelengths	are	performed.	The	ratio	of	the	 fluorescence	 intensities	 665/620	 nm	 (acceptor/donor)	 enables	 the	calculation	of	Delta	F,	which	represents	the	relative	energy	transfer	rate	for	each	sample.	Finally,	 to	 subtract	medium	background,	prepare	 triplicate	of	PBS(1X)-Tween	20	only.		14. Start	 by	 setting	 the	 loading	 in	 an	 independent	 experiment.	 It	 is	 preferable	 that	the	 loading	 curves	 remain	 linear	 (not	 reaching	 a	 plateau)	 as	 over-saturation	of	the	 biosensor	 is	 likely	 to	 induce	 the	 loading	 of	 a	 non-specific	 second	 layer	 of	protein	or	peptide	that	will	dissociate	during	the	following	baseline	step.	It	is	also	possible	 to	 stop	 the	 loading	before	 the	plateau	appears.	Proper	 loading	 control	consists	in	the	absence	of	loading	of	the	same	protein	in	its	non-biotinylated	form	and	at	the	same	concentration.		15. If	 possible,	 set	 the	 loadings	 of	 the	 relevant	 peptide	 and	 of	 the	 non-relevant	peptide	so	they	reach	the	same	light	deviation.		16. Make	a	preliminary	run	to	determine	the	analyte	concentration	range.	Typically,	prepare	4	to	5	concentration	points,	in	serial	log	dilutions	(dividing	concentration	by	ten	at	each	dilution),	starting	at	10	times	the	expected	Kd.	Select	the	range	in	which	clear	association	curves	are	visible	while	not	over-spending	your	sample.	 		 17. Interferometry	allows	measuring	the	dissociation	constant	of	a	protein	complex	(Kd),	 even	 for	 the	 medium-high	 affinities	 of	 signalling	 modules.	 The	 present	methodology	describes	 the	analysis	of	 the	association	between	a	peptide	and	 a	protein.	This	type	of	complex	has	a	very	low	affinity	and	since	the	measurement	of	 the	 Kd	 requires	 5	 association	 curves	 of	 the	 protein	 over	 the	 peptide,	 the	quantity	of	protein	necessary	may	be	high	(up	to	milligrams).	You	may	however	observe	 the	 interaction	 between	 the	 peptide	 and	 the	 protein	 at	 one	 single	concentration,	even	if	it	does	not	provide	a	Kd.		
18. This	methodology	can	also	be	used	to	measure	the	interaction	between	the	two	partner-proteins.	 In	 that	 case,	peptide	a	 should	be	 replaced	by	 the	biotinylated	partner	of	β-arrestin.		 19. It	 is	 important	 to	appreciate	 that	 it	may	be	difficult	 to	visualize	 the	 interaction	between	2	partners	when	their	molecular	weight	is	more	than	100-fold	different.	This	drawback	can	be	overcome	when	the	smallest	of	the	2	proteins	is	loaded	on	the	 biosensor.	 This	 is	 why	 it	 is	 important	 here	 to	 load	 the	 peptide	 on	 the	biosensor	and	not	the	protein.	 			  
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Figure legends 	Figure	 1:	 A.	 Principle	 of	 the	 GST-pulldown	 experiment	 with	 purified	 proteins.	 B.	Representative	 experiment	 to	 illustrate	 the	 disruption	 of	 the	 Raf1/	 β-arrestin	 1	interaction	by	a	competing	peptide	(73-ISPFEHQTY-81).	 In	each	condition,	25	ng	of	β-arrestin	1	are	added,	whereas	GST-Raf1-RBD	is	not	present	 in	 the	 last	 lane.	The	 same	membrane	hybridized	with	an	anti-GST	antibody	to	monitor	the	pulled-down	amount	of	GST-Raf-RBD	is	shown	below.	C.	Quantification	of	three	independent	experiments.		Figure	 2:	A.	 Principle	 of	 the	HTRF	 experiment.	B.	 Quantification	 of	 three	 independent	experiments	 showing	 β-arrestin	 1	 interaction	 with	 competing	 peptides	 after	 3hrs	 of	incubation.	 Sequences	 of	 the	 peptides	 are	 given	 in	 Note	 9.	 The	 control	 peptide	 is	 a	portion	of	the	sequence	of	the	C5	complement	protein.	Different	letters	above	the	bars	indicate	 statistically	 significant	 differences.	 C.	 Quantification	 of	 three	 independent	experiments	 showing	 β-arrestin	 1	 interaction	 with	 selected	 competing	 peptides	 after	either	1hr,	3hrs	or	3	days	of	incubation.		Figure	3:	A.	Principle	of	the	interferometry	experiment:	biotinylated	specific	peptide	or	control	 peptide	 binds	 to	 the	 streptavidin	 tip.	 β-arrestin	 then	 binds	 to	 the	 interfering	peptide	but	not	to	the	control	peptide.	B.	Sample	plate	scheme.	Samples	and	buffer	are	loaded	on	the	black	96-well	plate	as	shown	here.	The	peptides	α	and	γ	are	prepared	at	one	single	concentration	whereas	protein	β	is	prepared	in	five	concentrations.	Well	A4	contains	only	kinetic	buffer	and	will	be	used	as	control.	C.	Representative	experiments	to	 illustrate	 the	 observation	 by	 biolayer	 interferometry	 of	 the	 specific	 interaction	between	the	competing	peptide	ERK2-3	and	β-arrestin	1.		Figure	4:	Principles	for	refining	the	design	of	peptides.	See	text	for	details.		 	
			 	
			 	
			 	
	
